This inventor holds 32 USPTO granted patents and 1 published patent application and 9 EPO patents, primarily in Prostaglandin Synthesis. Top assignees: Chirogate International Inc., Irogate International Inc., Other. Active years: 2009-2026.
Location History:
- Taipei, TW (2009 - 2013)
- Yangmei, TW (2013 - 2024)
Company Filing History:
30 out of 30 
1 out of 1 
1 out of 834,411 Years Active: 2009-2026
Areas of Expertise:
Title: Innovations and Contributions of Shih-Yi Wei in Pharmaceutical Chemistry
Introduction
Shih-Yi Wei, based in Yangmei, Taiwan, has established himself as a prominent innovator within the pharmaceutical chemistry sector. With a portfolio comprising 28 patents, his work largely focuses on the development of novel analogues with important therapeutic implications.
Latest Patents
Among his most recent contributions, Wei has developed processes and intermediates for the preparation of carbaprostacyclin analogues. This invention outlines methodologies for synthesizing these analogues and includes details about cyclopentenone intermediates in both racemic and optically active forms. Additionally, he has worked on preparing benzoprostacyclin analogues and their corresponding intermediates. His developments in this area are significant, providing insights into cyclopentenone intermediates relevant for pharmaceutical applications.
Career Highlights
Throughout his professional journey, Shih-Yi Wei has worked with notable companies, including Chirogate International Inc. and Irogate International Inc. His experiences in these firms have contributed to his robust understanding and expertise in pharmaceutical innovations, reinforcing his standing as a key inventor in his field.
Collaborations
Wei's collaborative efforts have been instrumental in his success. He has shared working experiences with colleagues such as Yu-Chih Yeh and Min-Kuan Hsu, who have provided valuable insights and teamwork in the innovation process. These collaborations reflect a strong network of professionals committed to advancing pharmaceutical chemistry.
Conclusion
In summary, Shih-Yi Wei’s 28 patents, particularly in the area of carbaprostacyclin and benzoprostacyclin analogues, highlight his significant contributions to pharmaceutical innovation. His collaborative spirit and professional experiences with notable companies underscore his commitment to advancing medical science through innovative solutions. As the field progresses, Wei's work will undoubtedly continue to hold relevance and importance.